Anacor Pharmaceuticals Inc  

(Public, NASDAQ:ANAC)   Watch this stock  
Find more results for ANAC
-0.82 (-1.86%)
Real-time:   10:24AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 43.11 - 44.03
52 week 13.19 - 44.64
Open 43.99
Vol / Avg. 37,157.00/420,836.00
Mkt cap 1.86B
P/E 41.63
Div/yield     -
EPS 1.04
Shares 42.90M
Beta 1.51
Inst. own 100%
Mar 11, 2015
Q4 2014 Anacor Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 3, 2015
Anacor Pharmaceuticals Inc at Cowen Health Care Conference - 8:00AM EST - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -792.47% 492.02%
Operating margin -765.49% 529.00%
EBITD margin - -287.18%
Return on average assets -84.87% 75.94%
Return on average equity -169.77% 134.29%
Employees 79 -
CDP Score - -


1020 East Meadow Circle
PALO ALTO, CA 94303-4230
United States - Map
+1-650-5437500 (Phone)
+1-650-5437660 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Anacor Pharmaceuticals Inc is a United States-based biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company�s product candidates include topically administered dermatologic compounds-tavaborole (formerly AN2690), a topical antifungal for the treatment of onychomycosis, and AN2728, a topical anti-inflammatory for the treatment of atopic dermatitis and psoriasis. In addition, it is engaged in the development of other wholly-owned clinical product candidates, AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. The Company's clinical pipeline also includes internally developed topical and systemic boron-based compounds in development.

Officers and directors

Paul L. Berns Chairman of the Board, President, Chief Executive Officer
Age: 47
Bio & Compensation  - Reuters
Geoffrey M. Parker Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
Vincent P. Ippolito Executive Vice President, Chief Commercial Officer
Age: 55
Bio & Compensation  - Reuters
Sanjay Chanda Ph.D. Senior Vice President - Drug Development
Age: 49
Bio & Compensation  - Reuters
Kirk R. Maples Ph.D. Senior Vice President - Program Management
Age: 55
Bio & Compensation  - Reuters
Jacob J. Plattner Ph.D. Senior Vice President - Research
Age: 67
Bio & Compensation  - Reuters
Carmen R. Rodriguez Ph.D. Senior Vice President - Regulatory Affairs and Quality Assurance
Age: 65
Bio & Compensation  - Reuters
Lee T. Zane M.D. Senior Vice President - Clinical Development, Chief Medical Officer
Age: 44
Bio & Compensation  - Reuters
William J. Rieflin Lead Independent Director
Age: 54
Bio & Compensation  - Reuters
Anders D. Hove M.D. Independent Director
Age: 48
Bio & Compensation  - Reuters